ALPELISIB - Food and Drug Administration

Set ID
ffa47de3-b159-4b49-aed7-1387fbb5d311
Type
Indexing - product concept
Effective date
2019-08-28
Version
1
Source
DailyMed source

Mapped DailyMed Labels#

Label, Relation, Manufacturer table
LabelRelationManufacturerEffective
These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY ® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019Product nameNovartis Pharmaceuticals Corporation2026-10-28
These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019Product nameNovartis Pharmaceuticals Corporation2026-10-27
These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY. PIQRAY ® (alpelisib) tablets, for oral use Initial U.S. Approval: 2019Product nameNovartis Pharmaceuticals Corporation2025-12-15
These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019Product nameNovartis Pharmaceuticals Corporation2025-11-04
These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019Product nameNovartis Pharmaceuticals Corporation2025-07-23